HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Raises Price Target to $12

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target from $8 to $12.